Quantcast

Latest Chronic myelogenous leukemia Stories

2012-04-24 22:29:26

Although people generally talk about "cancer", it is clear that the disease occurs in a bewildering variety of forms. Even single groups of cancers, such as those of the white blood cells, may show widely differing properties. How do the various cancers arise and what factors determine their progression? Clues to these two issues, at least for leukemias, have now been provided by Boris Kovacic and colleagues at the University of Veterinary Medicine, Vienna (Vetmeduni Vienna). The results are...

2012-04-05 21:10:02

Researchers reporting in the April Cell Stem Cell, a Cell Press publication, have found a way to stop leukemia stem cells in their tracks. The advance in mice suggests that a combination approach to therapy might stamp out chronic myeloid leukemia (CML) for good. That's in contrast to the vast majority of CML patients taking drugs like imatinib (aka Gleevec) today, who often go into remission only to see their cancer return again. It is those lingering leukemia stem cells, which stubbornly...

2012-03-29 09:10:43

Change in registry protocols and laboratory practices cited Researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues from the UF Shands Cancer Center in Gainesville, Fla., have found that cases of myeloid malignancies are being underreported since a change in registry protocols and laboratory practices starting in 2001. Their study is published in a recent issue of Cancer Epidemiology, Biomarkers and Prevention, a publication of the American Association for Cancer Research....

2012-03-19 05:13:45

A multi-national research team led by scientists at Duke-NUS Graduate Medical School has identified the reason why some patients fail to respond to some of the most successful cancer drugs. Tyrosine kinase inhibitor drugs (TKIs) work effectively in most patients to fight certain blood cell cancers, such as chronic myelogenous leukemia (CML), and non-small-cell lung cancers (NSCLC) with mutations in the EGFR gene. These precisely targeted drugs shut down molecular pathways that keep...

2012-02-27 07:26:30

A new study has found that patients with chronic myeloid leukemia (CML) who have not responded to interferon treatments experience long-term benefits when they switch to the targeted drug imatinib. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that imatinib is the treatment of choice for these patients. Imatinib, a drug that blocks the protein made by a particular cancer-causing gene, has revolutionized the treatment and...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related